<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01992198</url>
  </required_header>
  <id_info>
    <org_study_id>SAP BUNDLE-ANTIBIOTICS</org_study_id>
    <secondary_id>12411950500</secondary_id>
    <nct_id>NCT01992198</nct_id>
  </id_info>
  <brief_title>Multi-center Clinical Study of Early Antibios of Severe Acute Pancreatitis</brief_title>
  <official_title>Escalade or Deseacalade Antibiotic Use in Severe Acute Pancreatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erzhen Chen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Strategy of antibiotic therapy in SAP,De-escalate (cefoperazone+metronidazole) or Escalate
      (meropenem) therapy,which one is better.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SAP is a serious and life-threatening disease and requires intensive and aggressive
      management of multiple organ failure and severe infectious complications that can develop in
      these patients. The most common cause of death in patients suffering from severe acute
      pancreatitis (SAP) is the infection of pancreatic necrosis by enteric bacteria with mortality
      rates of 30% (range 14- 62%),spurring the discussion of whether or not prophylactic
      antibiotic administration could be a beneficial approach. Pancreatic infections are more
      often monomicrobial, especially E. coli in the two first weeks (100% and 62.5%) of onset,
      with a shift from gram-negative to gram-positive as the pancreatitis progressed.

      In order to evaluate the benefit of prophylactic antibiotic application, a number of
      randomized controlled clinical trials have been published over the past 15 years. Since the
      results were conflicting and most studies were of low methodological quality and/or
      statistically underpowered, meta-analyses have been performed to assess this important issue.
      However, their results ranged from absolutely no effect of antibiotic prophylaxis to positive
      effects regarding mortality, the incidence of infected pancreatic necrosis and the incidence
      of extra pancreatic infections.

      In order to provide reliable evidence of the effect of antibiotherapy strategy in SAP, we
      performed a prospective randomized multicenter clinical trial.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pancreatic or peripancreatic infection</measure>
    <time_frame>28-day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>cost of management of SAP</measure>
    <time_frame>90-day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiology resistance</measure>
    <time_frame>90-day</time_frame>
    <description>sputum, urine and blood culture will be done once or twice per week if needed. bill or other culutre will be done when the patient is undergoing operation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pancreatitis,Acute Necrotizing</condition>
  <arm_group>
    <arm_group_label>cefoperazone + metronidazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cefoperaozone 2g q8h + MDZ 0.5g q8h Oral care Somatostatin 3-6mg per 24h enteral nutrition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>meropenem</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Meropenem 0.5g q6h or adapted with renal function. Oral care Somatostatin 3-6mg per 24h enteral nutrition</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cefoperazone + metronidazole</intervention_name>
    <description>1.Clinical parameters (2 of 3):
1)temperature&lt;37.8℃ or 2)HR &lt;100bpm or 3)SpO2 &gt;95% 2.Laboratory parameters (3 of 3):
1)CRP or 2)PCT reduction 70% compared to zenith for 2 consecutive samples 3)WBC &lt;12×10E9/L for 2 consecutive samples 3.Image parameter (1 of 1): liquid collection developed &lt;30% compared to that of 72h</description>
    <arm_group_label>meropenem</arm_group_label>
    <other_name>Cefobid</other_name>
    <other_name>Metronidazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>oral care by chlorhexidine gluconate</intervention_name>
    <description>oral care by 0.2% chlorhexidine gluconate twice daily</description>
    <arm_group_label>cefoperazone + metronidazole</arm_group_label>
    <arm_group_label>meropenem</arm_group_label>
    <other_name>chlorhexidine gluconate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>enteral nutrition</intervention_name>
    <arm_group_label>cefoperazone + metronidazole</arm_group_label>
    <arm_group_label>meropenem</arm_group_label>
    <other_name>Enteral Nutritional Suspension(SP) by NUTRICIA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Somatostatin</intervention_name>
    <arm_group_label>cefoperazone + metronidazole</arm_group_label>
    <arm_group_label>meropenem</arm_group_label>
    <other_name>somatostatin by merk</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meropenem</intervention_name>
    <description>All patients in cefo-group do not meet 1 of 3 laboratory parameter or image parameter or 2 of 3 clinical parameters.
1.Clinical parameters (2 of 3):
1)temperature&lt;37.8℃ or 2)HR &lt;100bpm or 3)SpO2 &gt;95% 2.Laboratory parameters (3 of 3):
1)CRP or 2)PCT reduction 70% compared to zenith for 2 consecutive samples 3)WBC &lt;12×10E9/L for 2 consecutive samples 3.Image parameter (1 of 1): liquid collection developed &lt;30% compared to that of 72h</description>
    <arm_group_label>cefoperazone + metronidazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  severe Acute Pancreatitis according to Atlanta criteria revisited in 2012

        Exclusion Criteria:

          -  concurrent sepsis or (peri)pancreatic infection caused by a second disease

          -  patients with chronic organ failure (chronic renal failure needs kidney replacement,
             chronic heart failure, decompensate hepatic cirrhosis, chronic obstructive pulmonary
             disease)

          -  recurrent or endoscopic retrograde cholangiopancreatography (ERCP), or traumatic or
             operative pancreatitis

          -  pregnancy, malignancy or immunodeficiency

          -  a history of allergy to meropenem, cefoperazone and metronidazole

          -  a history of antibiotic administration within 48 h prior to enrollment

          -  possible death within 48 h after enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Er-Zhen Chen, M.D. &amp; Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>En-Qiang Mao, M.D. &amp; Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhi-Tao Yang, M.D. &amp; Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erzhen Chen, M.D</last_name>
    <phone>86-13901753478</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Enqiang Mao, M.D</last_name>
    <phone>86-13501747906</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Depatrment of EICU,Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erzhen Chen, M.D</last_name>
      <phone>86-13901753478</phone>
    </contact>
    <contact_backup>
      <last_name>Enqiang , Mao</last_name>
      <phone>86-13501747906</phone>
    </contact_backup>
    <investigator>
      <last_name>Zhitao Yang, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2013</study_first_submitted>
  <study_first_submitted_qc>November 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2013</study_first_posted>
  <last_update_submitted>November 18, 2013</last_update_submitted>
  <last_update_submitted_qc>November 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Erzhen Chen</investigator_full_name>
    <investigator_title>Professer</investigator_title>
  </responsible_party>
  <keyword>antibiothearpy strategy</keyword>
  <keyword>cefoperazone</keyword>
  <keyword>metronidazole</keyword>
  <keyword>meropenem</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Pancreatitis, Acute Necrotizing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorhexidine</mesh_term>
    <mesh_term>Chlorhexidine gluconate</mesh_term>
    <mesh_term>Meropenem</mesh_term>
    <mesh_term>Sulperazone</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Thienamycins</mesh_term>
    <mesh_term>Cefoperazone</mesh_term>
    <mesh_term>Somatostatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

